Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics.

See related article by de Bono et al., p. XX

This content is only available via PDF.
You do not currently have access to this content.